The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Motion Sickness

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Motion Sickness


Psychiatry related information on Motion Sickness


High impact information on Motion Sickness


Chemical compound and disease context of Motion Sickness

  • Comparison with placebo indicated that transdermal scopolamine provided protection against motion sickness at a significance level of p = 0.0001 and oral dimenhydrinate at a level of p = 0.05 [16].
  • For motion sickness, control can be achieved with various antagonists of muscarinic or histamine H1-receptors [17].
  • Hyoscine (scopolamine) is a competitive inhibitor of the muscarinic receptors of acetylcholine and it has been shown to be one of the most effective agents for preventing motion sickness [18].
  • In the motion sickness procedure, the DeltaT(forearm-fingertip) response was significantly attenuated, indicating a blunted vasoconstrictor response, and rectal temperature decreased at a faster rate [19].
  • Marked difference across the motion sickness susceptibility spectrum in the condition on discharge of lithium and antidepressant treated patients was also found, when compared to other drug therapies, suggesting specific drug responses by the motion sick group [20].

Biological context of Motion Sickness

  • Collectively, these results indicate that LY228729 is potent 5-HT1A agonist with bioavailability properties sufficient for clinical evaluation and with efficacy in preclinical models of anxiety, sexual disorders and motion sickness [21].

Anatomical context of Motion Sickness


Gene context of Motion Sickness

  • This may include indirect effects via receptors in the signal cascade behind the 5-HT(3) receptor channel complex such as substance P receptors and muscarinic receptors; this needs further investigation since ginger is effective against motion sickness which is cured by some vanilloids and by anticholinergics such as scopolamine [27].
  • Peripheral release of ENDO and ACTH may follow release of AVP; however, given the extensive and complex functional interactions that exist between AVP and the opiate systems, it is not yet possible to define a clear role for ENDO in the etiology of motion sickness [28].
  • Higher post-stress levels of AVP (p < 0.04) and ACTH (p < 0.02) were correlated with greater resistance to motion sickness [28].
  • Increased secretion of growth hormone, prolactin, antidiuretic hormone, and cortisol induced by the stress of motion sickness [29].
  • Furthermore, increases in vasoactive intestinal peptide levels participate in motion sickness [30].

Analytical, diagnostic and therapeutic context of Motion Sickness


  1. Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs. Bountra, C., Gale, J.D., Gardner, C.J., Jordan, C.C., Kilpatrick, G.J., Twissell, D.J., Ward, P. Oncology (1996) [Pubmed]
  2. Effect of ondansetron on nausea and vomiting after middle ear surgery during general anaesthesia. Honkavaara, P. British journal of anaesthesia. (1996) [Pubmed]
  3. Effects of histamine and betahistine on rat medial vestibular nucleus neurones: possible mechanism of action of anti-histaminergic drugs in vertigo and motion sickness. Wang, J.J., Dutia, M.B. Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale. (1995) [Pubmed]
  4. Neurological disorders and travel. Awada, A., Kojan, S. Int. J. Antimicrob. Agents (2003) [Pubmed]
  5. Effects of dimenhydrinate on gastric tachyarrhythmia and symptoms of vection-induced motion sickness. Muth, E.R., Jokerst, M., Stern, R.M., Koch, K.L. Aviation, space, and environmental medicine. (1995) [Pubmed]
  6. Impaired gastric slow waves induced by spatial disorientation and effect of domperidone. Kono, T., Tokumaru, O., Mizumoto, C., Tatsuno, J., Chen, J.D. Am. J. Gastroenterol. (1999) [Pubmed]
  7. Autogenic-feedback training exercise is superior to promethazine for control of motion sickness symptoms. Cowings, P.S., Toscano, W.B. Journal of clinical pharmacology. (2000) [Pubmed]
  8. Effect of tryptophan depletion on symptoms of motion sickness in migraineurs. Drummond, P.D. Neurology (2005) [Pubmed]
  9. Vestibular, central and gastral triggering of emesis. A study on individual susceptibility in rats. Hasegawa, S., Takeda, N., Morita, M., Horii, A., Koizuka, I., Kubo, T., Matsunaga, T. Acta Otolaryngol. (1992) [Pubmed]
  10. A systematic review of the applicability and efficacy of eye exercises. Rawstron, J.A., Burley, C.D., Elder, M.J. Journal of pediatric ophthalmology and strabismus. (2005) [Pubmed]
  11. Transderm Scop for prevention of motion sickness. Johnson, P., Hansen, D., Matarazzo, D., Petterson, L., Swisher, C., Trappolini, A. N. Engl. J. Med. (1984) [Pubmed]
  12. Alleviation of motion sickness by nifedipine. Marley, J.E., Joy, M.D. Lancet (1987) [Pubmed]
  13. Pharmacology in space. Part 2. Controlling motion sickness. Lathers, C.M., Charles, J.B., Bungo, M.W. Trends Pharmacol. Sci. (1989) [Pubmed]
  14. Cinnarizine in the prophylaxis of seasickness: laboratory vestibular evaluation and sea study. Shupak, A., Doweck, I., Gordon, C.R., Spitzer, O. Clin. Pharmacol. Ther. (1994) [Pubmed]
  15. Transdermal scopolamine, oral meclizine, and placebo in motion sickness. Dahl, E., Offer-Ohlsen, D., Lillevold, P.E., Sandvik, L. Clin. Pharmacol. Ther. (1984) [Pubmed]
  16. Transdermal scopolamine in the prevention of motion sickness at sea. Price, N.M., Schmitt, L.G., McGuire, J., Shaw, J.E., Trobough, G. Clin. Pharmacol. Ther. (1981) [Pubmed]
  17. Pharmacological agents affecting emesis. A review (Part II). Mitchelson, F. Drugs (1992) [Pubmed]
  18. Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Clissold, S.P., Heel, R.C. Drugs (1985) [Pubmed]
  19. Motion sickness potentiates core cooling during immersion in humans. Mekjavic, I.B., Tipton, M.J., Gennser, M., Eiken, O. J. Physiol. (Lond.) (2001) [Pubmed]
  20. Motion sickness--key to neurobiologic variation. Mirabile, C.S., Glueck, B.C. The Journal of clinical psychiatry. (1979) [Pubmed]
  21. Preclinical studies on LY228729: a potent and selective serotonin1A agonist. Foreman, M.M., Fuller, R.W., Leander, J.D., Benvenga, M.J., Wong, D.T., Nelson, D.L., Calligaro, D.O., Swanson, S.P., Lucot, J.B., Flaugh, M.E. J. Pharmacol. Exp. Ther. (1993) [Pubmed]
  22. Phenytoin for motion sickness: clinical evaluation. Knox, G.W., Woodard, D., Chelen, W., Ferguson, R., Johnson, L. Laryngoscope (1994) [Pubmed]
  23. Histamine and related substances influence neurotransmission in the semicircular canal. Housley, G.D., Norris, C.H., Guth, P.S. Hear. Res. (1988) [Pubmed]
  24. Catecholaminergic responses to rotational stress in rat brain stem: implications for amphetamine therapy of motion sickness. Takeda, N., Morita, M., Yamatodani, A., Wada, H., Matsunaga, T. Aviation, space, and environmental medicine. (1990) [Pubmed]
  25. Histaminergic mechanism of motion sickness. Neurochemical and neuropharmacological studies in rats. Takeda, N., Morita, M., Kubo, T., Yamatodani, A., Watanabe, T., Wada, H., Matsunaga, T. Acta Otolaryngol. (1986) [Pubmed]
  26. Area postrema lesions in rats enhance the magnitude of body rotation-induced conditioned taste aversions. Ossenkopp, K.P. Behavioral and neural biology. (1983) [Pubmed]
  27. Mode of action of gingerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor channel and contraction of isolated guinea-pig ileum. Abdel-Aziz, H., Windeck, T., Ploch, M., Verspohl, E.J. Eur. J. Pharmacol. (2006) [Pubmed]
  28. beta-Endorphin and arginine vasopressin following stressful sensory stimuli in man. Kohl, R.L. Aviation, space, and environmental medicine. (1992) [Pubmed]
  29. Increased secretion of growth hormone, prolactin, antidiuretic hormone, and cortisol induced by the stress of motion sickness. Eversmann, T., Gottsmann, M., Uhlich, E., Ulbrecht, G., von Werder, K., Scriba, P.C. Aviation, space, and environmental medicine. (1978) [Pubmed]
  30. Hormonal changes after parabolic flight: implications on the development of motion sickness. Drummer, C., Stromeyer, H., Riepl, R.L., König, A., Strollo, F., Lang, R.E., Maass, H., Röcker, L., Gerzer, R. Aviation, space, and environmental medicine. (1990) [Pubmed]
  31. Comparison of granisetron, droperidol, and metoclopramide for prevention of postoperative vomiting in children with a history of motion sickness undergoing tonsillectomy. Fujii, Y., Tanaka, H. J. Pediatr. Surg. (2001) [Pubmed]
  32. Suncus murinus as a new experimental model for motion sickness. Ueno, S., Matsuki, N., Saito, H. Life Sci. (1988) [Pubmed]
  33. Prophylactic ondansetron for post-operative emesis: meta-analysis of its effectiveness in patients with and without a previous history of motion sickness. Figueredo, E., Canosa, L. European journal of anaesthesiology. (1999) [Pubmed]
WikiGenes - Universities